Pancreatitis

Overview

Pancreatitis is an inflammatory condition of the pancreas resulting from premature intrapancreatic activation of digestive enzymes, leading to autodigestion of pancreatic tissue and a systemic inflammatory cascade. It is classified as acute pancreatitis (AP) — a discrete episode with potential for full recovery — or chronic pancreatitis (CP) — a progressive, irreversible condition characterized by fibrosis, exocrine insufficiency, and endocrine dysfunction. These entities share common etiological pathways but differ substantially in their natural history, management priorities, and long-term consequences.

Acute pancreatitis is one of the most common gastrointestinal causes of hospital admission in the United States, accounting for more than 275,000 hospitalizations annually (Peery et al., 2019). Approximately 80% of cases are mild and self-limiting; however, 15–20% progress to severe disease with systemic complications and mortality rates exceeding 30% in the setting of infected necrotizing pancreatitis. Chronic pancreatitis affects an estimated 50 per 100,000 adults and carries significant burdens of chronic pain, malabsorption, diabetes mellitus, and pancreatic cancer risk.

For the BSN-prepared nurse, pancreatitis demands expertise in rapid fluid assessment, pain management, nutritional support, and the recognition of life-threatening complications. The nurse is central to early detection of clinical deterioration, coordination of interprofessional care, and meaningful patient and family education aimed at reducing recurrence and improving long-term quality of life.

---

Pathophysiology

Exocrine Pancreatic Function

The exocrine pancreas produces approximately 1.5–2 liters of enzyme-rich, bicarbonate-buffered juice per day. Under normal physiological conditions, digestive enzymes — including trypsinogen, chymotrypsinogen, proelastase, phospholipase A2, and lipase — are synthesized as inactive proenzymes (zymogens) and stored within membrane-bound zymogen granules in acinar cells. Premature activation within the acinar cell or pancreatic duct is normally prevented by several protective mechanisms: low intracellular calcium concentrations, rapid export of zymogens to the duodenum, co-packaging with trypsin inhibitors (serine protease inhibitor Kazal type 1, or SPINK1), and the alkaline ductal environment.

Acute Pancreatitis: Premature Enzyme Activation

The inciting event in acute pancreatitis is the premature, intracellular activation of trypsinogen to trypsin within acinar cells. Regardless of the specific etiology, the unifying mechanism involves disruption of normal zymogen export and a rise in cytosolic calcium that triggers autoactivation. Once formed, trypsin activates the full complement of digestive zymogens in a cascade — lipase, elastase, phospholipase A2, and kallikrein — all of which begin digesting the surrounding pancreatic and peripancreatic tissue.

This autodigestion triggers a profound local and systemic inflammatory response. Acinar injury releases cytokines including TNF-α, IL-1β, IL-6, and IL-8, which recruit neutrophils and macrophages, amplify inflammation, and promote vascular permeability. In severe acute pancreatitis, this inflammatory response escapes local containment and produces systemic inflammatory response syndrome (SIRS), which can progress to multi-organ dysfunction syndrome (MODS) affecting the lungs, kidneys, cardiovascular system, and coagulation cascade.

Common Etiologies

Biliary disease (gallstones) and chronic alcohol use together account for approximately 70–80% of all acute pancreatitis cases in the United States. Gallstone pancreatitis occurs when a stone transiently or persistently obstructs the common bile duct at the level of the ampulla of Vater, causing reflux of bile into the pancreatic duct or increased ductal pressure that disrupts acinar cell function. Alcohol-related pancreatitis involves direct toxic injury to acinar cells, promotion of premature zymogen activation, altered ductal secretion, and oxidative stress — mechanisms that explain the cumulative, dose-dependent nature of alcoholic pancreatic injury.

Less common but clinically significant causes include:

• Hypertriglyceridemia: Triglyceride levels > 1,000 mg/dL (often > 2,000 mg/dL) generate free fatty acids via pancreatic lipase activity, producing direct acinar toxicity and microvascular injury. It is the third most common cause of acute pancreatitis.
• Post-ERCP pancreatitis: A complication occurring in 3–5% of endoscopic retrograde cholangiopancreatography (ERCP) procedures, caused by ductal trauma, thermal injury, or contrast instillation.
• Medications: Azathioprine, mercaptopurine, didanosine, valproic acid, tetracyclines, furosemide, and thiazide diuretics are among the most commonly implicated drugs.
• Hypercalcemia: Elevated serum calcium promotes premature trypsinogen activation within the acinar cell; associated with hyperparathyroidism and malignancy.
• Trauma and surgery: Blunt abdominal trauma and post-surgical injury, including pancreatic ischemia during prolonged hypotension.
• Autoimmune pancreatitis (AIP): A steroid-responsive, IgG4-mediated inflammatory condition that may mimic pancreatic carcinoma on imaging.
• Idiopathic: Approximately 15–20% of cases have no identifiable cause after initial evaluation; microlithiasis (biliary sludge), sphincter of Oddi dysfunction, and genetic variants (PRSS1, CFTR, SPINK1 mutations) account for many cases on further investigation.

Chronic Pancreatitis: Fibrosis and Functional Loss

Chronic pancreatitis results from repeated or sustained pancreatic injury leading to progressive acinar cell loss, ductal distortion, and replacement of functional tissue by fibrous scar. The predominant pathophysiological model — the sentinel acute pancreatitis event (SAPE) hypothesis — proposes that an initial episode of acute pancreatitis triggers perilobular inflammation and stellate cell activation; repeated insults convert this reversible process into irreversible fibrosis. The toxic-metabolic hypothesis further attributes chronic injury directly to sustained exposure to ethanol metabolites and oxidative stress.

End-stage chronic pancreatitis is characterized by:

• Exocrine insufficiency: Loss of > 90% of acinar mass results in fat malabsorption (steatorrhea), fat-soluble vitamin deficiencies (A, D, E, K), protein malabsorption, and weight loss.
• Endocrine insufficiency: Progressive destruction of islet cells produces “pancreatogenic” (type 3c) diabetes mellitus, which carries unique management challenges including unpredictable hypoglycemia due to concurrent glucagon deficiency.
• Ductal hypertension: Strictures and protein plugs calcify into pancreatic stones, obstructing ductal outflow and producing recurrent pain episodes.
• Pancreatic cancer risk: Chronic pancreatitis confers a 5–15-fold increased lifetime risk of pancreatic ductal adenocarcinoma.

---

Clinical Presentation

Acute Pancreatitis

The hallmark presentation of acute pancreatitis is severe, constant epigastric pain that radiates to the back in approximately 50% of patients. The pain typically reaches maximum intensity within 30 minutes of onset, persists for hours to days, and is frequently described as boring, deep, or knife-like. It is worsened by supine positioning and often partially relieved by sitting forward (the fetal position). Nausea and vomiting are present in the majority of patients and do not relieve the pain — distinguishing pancreatitis from some other gastrointestinal conditions.

Key physical examination findings include:

• Abdominal tenderness: Epigastric tenderness is nearly universal; peritoneal signs (rigidity, rebound) suggest severe disease or complications such as perforation.
• Abdominal distension: Ileus and retroperitoneal fluid collections contribute to bloating and hypoactive bowel sounds.
• Fever: Mild fever (38–39°C) is common in the first 48–72 hours due to inflammation; sustained high fever after 72 hours raises concern for infected necrosis or other septic complications.
• Tachycardia and hypotension: Reflect third-spacing, vomiting-induced volume loss, and vasodilation from SIRS.
• Grey Turner sign: Flank ecchymosis indicating retroperitoneal hemorrhage; associated with hemorrhagic pancreatitis (rare but serious).
• Cullen sign: Periumbilical ecchymosis; same significance as Grey Turner sign. Both signs appear 24–48 hours after hemorrhagic extension and are associated with high mortality.
• Jaundice: Suggests a biliary etiology with common bile duct obstruction (gallstone pancreatitis, pancreatic head edema).

Chronic Pancreatitis

Patients with chronic pancreatitis typically present with recurrent or continuous epigastric and left upper quadrant pain that may radiate to the back. Pain is often postprandial and associated with nausea; patients frequently restrict eating to avoid pain, contributing to progressive weight loss and malnutrition. Over time, as progressive fibrosis destroys enzyme-producing acinar cells, some patients paradoxically experience a reduction in pain (the so-called “burn-out” phenomenon), while malabsorptive and endocrine symptoms become the dominant clinical concerns.

Key features of chronic pancreatitis include:

• Steatorrhea: Bulky, foul-smelling, oily stools that are difficult to flush — a hallmark of fat malabsorption due to lipase deficiency.
• Weight loss and malnutrition: Result from a combination of dietary restriction, malabsorption, and the catabolic demands of chronic inflammation.
• New-onset or worsening diabetes: Type 3c diabetes differs from type 1 and type 2 in that glucagon secretion is also impaired, making hypoglycemia both more frequent and less reliably sensed by the patient.
• Pancreatic calcifications: Visible on plain abdominal radiograph or CT in advanced disease; pathognomonic for chronic pancreatitis.

---

Diagnostic Evaluation

Acute Pancreatitis: Diagnostic Criteria

The diagnosis of acute pancreatitis requires at least two of the following three criteria (Revised Atlanta Classification, 2012):

1. Clinical: Characteristic abdominal pain (acute onset, severe, epigastric, radiation to back).
2. Laboratory: Serum amylase or lipase ≥ 3 times the upper limit of normal (ULN). Lipase is preferred because it rises earlier, remains elevated longer, and is more specific for pancreatic injury.
3. Imaging: CT findings consistent with acute pancreatitis (peripancreatic fat stranding, pancreatic edema, or necrosis).

Cross-sectional imaging with contrast-enhanced computed tomography (CECT) is the gold standard for evaluating severity, identifying complications, and guiding intervention. CT is not routinely indicated at initial presentation for mild cases diagnosed clinically and biochemically, but is essential when diagnosis is uncertain, when the patient fails to improve within 48–72 hours, or when complications are suspected. The CT Severity Index (CTSI), which combines a morphological grade with the extent of pancreatic necrosis, provides a validated score that correlates with morbidity and mortality.

Key Laboratory Studies

Test	Clinical Significance
Serum lipase	Most sensitive and specific enzymatic marker; preferred over amylase; peaks at 24–48 h, remains elevated 8–14 days
Serum amylase	Rises within 2–12 h; returns to normal in 3–5 days; less specific (elevated in parotitis, bowel ischemia, renal failure)
C-reactive protein (CRP)	CRP > 150 mg/L at 48 h is a validated marker of severe AP and pancreatic necrosis
Complete blood count	Leukocytosis reflects inflammation; rising hematocrit (hemoconcentration) indicates third-spacing and predicts severity
BUN / creatinine	Rising BUN and creatinine indicate AKI from hypovolemia and/or systemic inflammation
Comprehensive metabolic panel	Hypocalcemia (fat saponification), hyperbilirubinemia, and elevated transaminases suggest biliary etiology
Triglycerides	Must be measured when etiology is unclear; levels > 1,000 mg/dL confirm hypertriglyceridemia-induced AP
Serum calcium	Hypocalcemia is a poor prognostic sign; hypercalcemia may be an etiological factor
Arterial blood gas (ABG)	PaO₂ < 60 mmHg or PaO₂/FiO₂ < 300 indicates acute respiratory failure / ARDS

Severity Classification: Revised Atlanta Classification (2012)

Severity	Definition
Mild AP	No organ failure; no local or systemic complications; typically resolves within 1 week
Moderately severe AP	Transient organ failure (resolves within 48 h) and/or local complications (fluid collections, necrosis) without persistent organ failure
Severe AP	Persistent organ failure (> 48 h) in one or more organ systems (cardiovascular, respiratory, renal); highest mortality

Ranson Criteria

The Ranson criteria use eleven clinical and laboratory variables measured at admission and at 48 hours to predict morbidity and mortality. While superseded in research settings by more dynamic scoring tools (APACHE II, BISAP), Ranson criteria remain widely taught and clinically referenced.

At admission: Age > 55 years, WBC > 16,000/mm³, blood glucose > 200 mg/dL, serum LDH > 350 IU/L, AST > 250 IU/L.

At 48 hours: Hematocrit decrease > 10 percentage points, BUN increase > 5 mg/dL, serum calcium < 8 mg/dL, PaO₂ < 60 mmHg, base deficit > 4 mEq/L, estimated fluid sequestration > 6 L.

A score of 0–2 predicts < 1% mortality; 3–4 predicts ~15% mortality; 5–6 predicts ~40% mortality; ≥ 7 predicts > 99% mortality.

---

Nursing Assessment

History and Risk Factor Identification

A thorough nursing history establishes the context for diagnosis, guides risk stratification, and informs the development of an individualized care plan. Key elements to elicit include:

• Pain characterization: Onset (sudden vs. gradual), location (epigastric, left upper quadrant, radiation to back), quality, severity (0–10 numeric scale), alleviating and aggravating factors, and prior similar episodes.
• Dietary history: Last oral intake (NPO assessment), high-fat meal before symptom onset, dietary patterns relevant to hypertriglyceridemia.
• Alcohol use history: Amount, frequency, duration, and type of alcohol consumed; use validated screening tools (AUDIT-C) and approach the topic in a non-judgmental, therapeutic manner.
• Medication review: Comprehensive review with attention to implicated agents (thiazides, furosemide, azathioprine, valproic acid, tetracyclines, didanosine, statins in rare cases).
• Medical and surgical history: Prior episodes of pancreatitis, known cholelithiasis, prior ERCP or abdominal surgery, history of hypertriglyceridemia, hyperparathyroidism, autoimmune disease, or malignancy.
• Family history: Hereditary pancreatitis (PRSS1 mutation), cystic fibrosis.

Pain Assessment

Pain assessment in pancreatitis must be systematic and continuous. Use a validated, consistent pain scale (numeric rating scale or behavioral pain scale in non-verbal patients) and document pain location, quality, intensity, radiation pattern, and temporal pattern at regular intervals and following any intervention. Note that pain intensity does not always correlate with disease severity — patients with severe necrotizing pancreatitis may occasionally report less dramatic pain as necrosis progresses.

Fluid Status and Hemodynamic Assessment

Hemodynamic instability and hypovolemia are the primary causes of early morbidity in acute pancreatitis. The following parameters must be monitored closely, particularly in the first 24–48 hours:

• Vital signs with particular attention to heart rate, blood pressure, mean arterial pressure (MAP), and respiratory rate
• Urine output via urinary catheter (goal ≥ 0.5 mL/kg/hr); oliguria is an early indicator of renal hypoperfusion
• Accurate intake and output (I&O), including emesis and any drainage
• Daily weights using the same scale, same time, same conditions
• Signs of volume depletion: tachycardia, hypotension, dry mucous membranes, decreased skin turgor, concentrated urine, rising BUN and creatinine
• Signs of volume overload (overresuscitation): peripheral edema, pulmonary crackles, increasing abdominal distension, worsening respiratory status

Respiratory Assessment

Pulmonary complications — including pleural effusions, atelectasis, and acute respiratory distress syndrome (ARDS) — occur in up to 30% of patients with severe acute pancreatitis. Diaphragmatic elevation from retroperitoneal fluid collections, pain-splinted breathing, and cytokine-mediated lung injury all contribute.

• Monitor SpO₂ continuously; apply supplemental oxygen to maintain SpO₂ ≥ 95%
• Auscultate lung fields every 2–4 hours for crackles, diminished breath sounds (pleural effusion), and adventitious sounds
• Monitor respiratory rate and work of breathing; tachypnea and use of accessory muscles are early signs of respiratory compromise
• Assess for cough, productive sputum, pleuritic chest pain, or dyspnea
• Review serial ABG results; a PaO₂/FiO₂ ratio < 300 meets criteria for ARDS

Abdominal Assessment

Abdominal assessment is performed at minimum every 4–8 hours and more frequently in severe or deteriorating cases:

• Inspect for distension, rigidity, and visible ecchymosis (Grey Turner and Cullen signs)
• Auscultate for bowel sounds in all four quadrants; hypoactive or absent sounds indicate ileus
• Palpate gently for tenderness, guarding, and rigidity — avoid deep palpation that may exacerbate pain or precipitate rupture of fluid collections
• Measure abdominal girth in patients with significant distension or suspected compartment syndrome
• Monitor for signs of peritonitis (fever, rebound tenderness, involuntary guarding, rigidity), which may indicate perforation or infected necrosis

---

Nursing Interventions

Fluid Resuscitation

Aggressive, goal-directed intravenous fluid resuscitation is the cornerstone of early acute pancreatitis management. The primary objective is to restore and maintain adequate intravascular volume to prevent ischemic complications — including pancreatic necrosis, AKI, and mesenteric ischemia — that result from the massive fluid shift into the retroperitoneal and peritoneal spaces.

Lactated Ringer’s solution (LR) is the preferred crystalloid for resuscitation in acute pancreatitis. Multiple randomized controlled trials and meta-analyses have demonstrated that LR reduces systemic inflammation and decreases the incidence of SIRS compared with normal saline (NS). The theoretical mechanism involves LR’s composition as a balanced, near-physiological solution that does not produce the hyperchloremic metabolic acidosis associated with large-volume NS infusion — an acidosis that itself promotes inflammation and impairs pancreatic perfusion.

Typical fluid administration rates range from 250–500 mL/hr in the first 24–48 hours, titrated to clinical response. Goals include:

• MAP ≥ 65 mmHg
• Urine output ≥ 0.5 mL/kg/hr
• Heart rate < 100 beats/min
• Improvement or normalization of hematocrit and BUN

Pain Management

Effective pain management is both a humanitarian priority and a clinical necessity, because uncontrolled pain drives physiological stress responses that worsen the systemic inflammatory burden. Current evidence-based practice recommends:

• Opioid analgesia as the first-line pharmacological approach for moderate to severe pain. Hydromorphone and morphine are most commonly used. The historical contraindication of morphine due to concern for Oddi sphincter spasm is not supported by contemporary clinical evidence and should not guide analgesic selection.
• Patient-controlled analgesia (PCA) may be used in appropriate patients to maintain consistent pain relief while minimizing nursing-administered bolus requirements.
• Multimodal analgesia — combining opioids with adjuncts such as acetaminophen, ketorolac (with attention to renal function and GI status), and epidural analgesia — reduces total opioid requirements and side effects.
• Positioning: Encourage the semi-Fowler or forward-leaning position, which may reduce tension on the inflamed pancreas and partially alleviate pain.

Assess pain using a consistent, validated scale before and after each intervention. Document the timing, dose, route, and patient response to all analgesics. Monitor for opioid-related adverse effects: respiratory depression (< 12 breaths/min warrants intervention), sedation, nausea, and constipation.

Nutritional Support

Nutritional management in pancreatitis has evolved substantially based on emerging evidence. The older paradigm of prolonged NPO status to “rest the pancreas” has been replaced by a more nuanced, patient-driven approach:

• Mild acute pancreatitis: Oral intake — beginning with a soft, low-fat diet rather than a clear liquid diet — may be resumed as soon as nausea and vomiting have resolved and the patient demonstrates return of appetite, typically within 24–72 hours. Early oral feeding reduces hospital length of stay and is not associated with worsening outcomes.
• Moderately severe and severe acute pancreatitis: Enteral nutrition (EN) via a nasojejunal (NJ) or nasogastric (NG) tube is strongly preferred over total parenteral nutrition (TPN). Multiple randomized controlled trials demonstrate that EN maintains gut barrier integrity, reduces bacterial translocation, decreases infectious complications (particularly infected necrosis), and is associated with lower mortality compared with TPN. EN should be initiated within 24–48 hours of admission if oral intake is not feasible.
• Total parenteral nutrition (TPN): Reserved for patients in whom the enteral route is not feasible (e.g., prolonged ileus, high-output fistula, intestinal failure). TPN carries risks of central line-associated bloodstream infection (CLABSI), hyperglycemia, and gut atrophy.

Patients with chronic pancreatitis and exocrine insufficiency require pancreatic enzyme replacement therapy (PERT) — taken with every meal and snack — to optimize fat and protein absorption and address steatorrhea. Fat-soluble vitamin supplementation (A, D, E, K) and monitoring for nutritional deficiencies are essential components of ongoing management.

Infection Prevention and Wound Care

Infected pancreatic necrosis (IPN) is the most feared complication of severe acute pancreatitis, occurring in 20–40% of patients with necrotizing pancreatitis and carrying a mortality rate of 15–35%. Unlike the infected or phlegmonous inflammation of the first week (which is sterile SIRS), IPN typically develops after the first week and results from translocation of gut flora into devitalized pancreatic tissue.

Key nursing responsibilities related to infection include:

• Strict hand hygiene and aseptic technique for all invasive procedures and vascular access
• Monitor for signs of secondary infection: sustained fever beyond 72–96 hours, rising WBC count, new hemodynamic instability, increasing pain after initial improvement, or a change in clinical trajectory
• Central line care per institutional CLABSI prevention bundles when TPN or vasoactive medications are required
• Wound assessment and care for patients who undergo percutaneous drainage or surgical necrosectomy

Blood Glucose Monitoring

Hyperglycemia in acute pancreatitis arises from inflammation-related insulin resistance, counter-regulatory hormone release, and — in severe cases — destruction of islet cells in the context of extensive pancreatic necrosis. Patients with underlying diabetes or those with significant parenchymal destruction are at particular risk.

• Monitor blood glucose every 4–6 hours (or more frequently per institutional protocol) in hospitalized patients with pancreatitis
• Target blood glucose 140–180 mg/dL for critically ill patients per current intensive care guidelines; tighter control (< 140 mg/dL) in stable ward patients may be appropriate
• Administer insulin per prescribed sliding scale or infusion protocol
• Monitor for hypoglycemia, particularly in patients with chronic pancreatitis and concurrent glucagon deficiency, who may have blunted counter-regulatory responses

---

Complications

Local Complications

Complication	Description	Timing	Nursing Implications
Acute peripancreatic fluid collection (APFC)	Homogeneous fluid adjacent to pancreas; no defined wall	First 4 weeks	Usually resolves spontaneously; monitor for expansion
Acute necrotic collection (ANC)	Mixed solid/liquid necrotic material; no defined wall	First 4 weeks	Requires close monitoring; infection surveillance
Pancreatic pseudocyst	Encapsulated fluid collection with defined fibrous wall; no solid components	> 4 weeks post-AP	Drain if symptomatic (pain, biliary/GI obstruction, infection)
Walled-off necrosis (WON)	Encapsulated heterogeneous collection with solid necrotic debris	> 4 weeks post-AP	Drain if infected or symptomatic; may require endoscopic, percutaneous, or surgical necrosectomy
Infected pancreatic necrosis (IPN)	Bacterial colonization of ANC or WON; confirmed by CT-guided aspiration or air in collection on CT	Usually > 1 week	Requires antibiotics (carbapenems preferred) and drainage; source of sepsis
Pancreatic duct disruption	Leak of pancreatic secretions due to ductal injury	Variable	Can lead to pancreatic ascites, pleural effusion, or fistula

Systemic Complications

• SIRS and sepsis: Cytokine storm from pancreatic inflammation; monitor qSOFA and SOFA scores, apply sepsis bundles promptly.
• Acute Respiratory Distress Syndrome (ARDS): Results from cytokine-mediated capillary leak in pulmonary vasculature; requires lung-protective ventilation (tidal volumes 6 mL/kg ideal body weight, PEEP titration, prone positioning in severe cases).
• Acute Kidney Injury (AKI): Both prerenal (from hypovolemia) and intrinsic (from SIRS-mediated renal microvascular injury); monitor urine output and creatinine trends vigilantly.
• Cardiovascular: Hypotension, tachyarrhythmias, pericardial effusion; hemodynamic monitoring and vasopressor support may be required.
• Hypocalcemia: Results from fat saponification and hypoalbuminemia; monitor for Chvostek and Trousseau signs, ECG changes (prolonged QT), and neuromuscular irritability; correct calcium and albumin levels.
• Coagulopathy and DIC: Severe inflammation activates the coagulation cascade; monitor PT, aPTT, fibrinogen, D-dimer, and platelet counts.
• Abdominal compartment syndrome: Massive fluid resuscitation combined with ileus, ascites, and retroperitoneal edema can elevate intra-abdominal pressure (> 20 mmHg with new organ dysfunction), impairing perfusion of all abdominal organs; bladder pressure monitoring may be required in high-risk patients.

---

Pharmacological Considerations

While pancreatitis management is primarily supportive, several pharmacological agents are central to nursing administration:

Agent / Class	Clinical Role	Nursing Considerations
Opioid analgesics (hydromorphone, morphine, fentanyl)	Pain control	Monitor respiratory rate, sedation, bowel function; have naloxone available; PCA requires patient education
Non-opioid analgesics (acetaminophen, ketorolac)	Multimodal analgesia adjuncts	Ketorolac: monitor renal function, avoid > 5 days; acetaminophen: monitor liver function, maximum 4 g/day
Antiemetics (ondansetron, metoclopramide, prochlorperazine)	Nausea/vomiting control	Monitor for QTc prolongation with ondansetron; metoclopramide may worsen ileus; assess effectiveness
Proton pump inhibitors (PPIs)	Stress ulcer prophylaxis	Administer as scheduled; oral route preferred when available; IV for NPO patients
Insulin	Hyperglycemia management	Monitor blood glucose per protocol; hypoglycemia risk especially in chronic pancreatitis; IV infusion requires close monitoring
Pancreatic enzyme replacement (PERT) (pancrelipase)	Exocrine insufficiency in chronic pancreatitis	Must be taken with meals; dose titration based on stool character and nutritional status; do not crush microspheres
Fat-soluble vitamins (A, D, E, K)	Replacement in exocrine insufficiency	Monitor levels; vitamin K deficiency prolongs PT; vitamin D deficiency contributes to metabolic bone disease
Carbapenems (imipenem, meropenem)	Infected pancreatic necrosis	Reserve for confirmed IPN; monitor for superinfection; C. difficile risk with prolonged use
Octreotide	Not routinely recommended for AP; may reduce output in pancreatic fistulas	Administer subcutaneously or IV per order; monitor blood glucose (may cause hypoglycemia or hyperglycemia)

---

Patient and Family Education

Effective patient and family education is critical to reducing recurrence, supporting recovery, and managing chronic pancreatitis. Education should be initiated early, delivered in a culturally sensitive manner at an appropriate health literacy level, and reinforced throughout the hospitalization and at discharge.

Acute Pancreatitis: Recurrence Prevention

The most common modifiable risk factors for recurrent acute pancreatitis are biliary disease and alcohol use disorder. Education should address:

• Biliary pancreatitis: Patients with gallstone pancreatitis should be educated about the need for cholecystectomy (typically laparoscopic) to prevent recurrence, which is recommended within 7 days of resolution of the acute episode in mild AP and after adequate recovery in moderate-to-severe cases.
• Alcohol cessation: Explain the direct relationship between alcohol use and pancreatic injury. Use motivational interviewing techniques; offer referral to addiction medicine, behavioral health services, and support groups (e.g., Alcoholics Anonymous). Avoid stigmatizing language.
• Dietary modifications during recovery: Low-fat diet in the convalescent period reduces the stimulatory load on recovering exocrine function; provide specific, practical food guidance rather than only general instructions.
• Signs and symptoms of recurrence or complications: Teach patients to recognize epigastric pain radiating to the back, nausea, vomiting, fever, or jaundice — and to seek prompt medical evaluation rather than managing symptoms at home.
• Medication review: Educate about the importance of reviewing all medications with their healthcare provider before initiating new drugs; advise against NSAID use without medical guidance.

Chronic Pancreatitis: Long-Term Management

Patients with chronic pancreatitis require comprehensive education addressing multiple dimensions of a complex, lifelong condition:

• Pain management strategies: Distinguish expected postprandial discomfort from pain requiring escalated intervention; emphasize the role of a low-fat diet (< 20–40 g fat/day), small frequent meals, and non-opioid analgesic strategies as first-line approaches.
• Pancreatic enzyme replacement therapy (PERT): Explain that lipase, protease, and amylase must be taken with every meal and fat-containing snack to achieve adequate absorption. Doses should not be taken at bedtime without a snack. Capsules should be swallowed whole; if opened, contents should not be chewed or placed in alkaline foods (will inactivate the microspheres).
• Dietary guidance: Low-fat diet with adequate protein; frequent small meals rather than large meals; avoidance of spicy and fatty foods; adequate hydration; consultation with a registered dietitian experienced in pancreatic disease.
• Diabetes self-management: Type 3c diabetes management is more complex than typical type 2 diabetes. Emphasize the risk of hypoglycemia (especially in patients on insulin), the importance of blood glucose monitoring, sick-day rules, and when to contact their provider.
• Alcohol and smoking cessation: Both alcohol and tobacco use accelerate progression of chronic pancreatitis and substantially increase pancreatic cancer risk. Provide referrals and cessation support at every encounter.
• Cancer surveillance: Explain the increased risk of pancreatic adenocarcinoma and the importance of follow-up imaging surveillance per their gastroenterologist’s recommendation.
• Mental health and quality of life: Chronic pain, dietary restrictions, fear of malignancy, and addiction concerns take a significant psychological toll. Assess for depression and anxiety; facilitate referral to behavioral health and pain management specialists.

---

Interprofessional Collaboration

Optimal management of pancreatitis — particularly severe acute pancreatitis and chronic pancreatitis — requires coordinated interprofessional care. The BSN nurse serves as a central communication hub across disciplines:

• Gastroenterology / Hepatology: Endoscopic management (ERCP for biliary pancreatitis, endoscopic necrosectomy), long-term chronic pancreatitis management, and cancer surveillance.
• Surgery: Laparoscopic cholecystectomy for biliary pancreatitis, surgical necrosectomy for refractory IPN, and management of pancreatic fistulas.
• Interventional Radiology: Percutaneous drainage of infected or symptomatic fluid collections.
• Critical Care / Intensivists: Hemodynamic management, mechanical ventilation, renal replacement therapy in severe cases.
• Nutrition Support: Registered dietitians and nutrition support teams for enteral and parenteral nutrition initiation, monitoring, and transitional feeding plans.
• Endocrinology: Management of type 3c diabetes and complex insulin regimens.
• Addiction Medicine / Behavioral Health: Alcohol and substance use disorder treatment, smoking cessation, and mental health support.
• Pain Management / Palliative Care: Consultation for refractory chronic pancreatitis pain, evaluation for celiac plexus block, and quality of life planning.
• Social Work and Case Management: Discharge planning, community resource referral (food security, transportation to follow-up, substance use treatment programs), and insurance navigation.

---

References and Evidence Base

The following sources represent the evidence base and professional consensus underlying the content of this entry. Faculty and students are encouraged to access primary literature through institutional library databases.

• Banks, P. A., Bollen, T. L., Dervenis, C., et al. (2013). Classification of acute pancreatitis — 2012: Revision of the Atlanta classification and definitions by international consensus. Gut, 62(1), 102–111.
• Gardner, T. B. (2021). Acute pancreatitis. Annals of Internal Medicine, 174(2), ITC17–ITC32.
• Leppäniemi, A., Tolonen, M., Tarasconi, A., et al. (2019). 2019 WSES guidelines for the management of severe acute pancreatitis. World Journal of Emergency Surgery, 14, 27.
• Peery, A. F., Crockett, S. D., Murphy, C. C., et al. (2019). Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: Update 2018. Gastroenterology, 156(1), 254–272.e11.
• Tenner, S., Baillie, J., DeWitt, J., & Vege, S. S. (2013). American College of Gastroenterology guideline: Management of acute pancreatitis. American Journal of Gastroenterology, 108(9), 1400–1416.
• Vege, S. S., DiMagno, M. J., Forsmark, C. E., Martel, M., & Barkun, A. N. (2018). Initial medical treatment of acute pancreatitis: American Gastroenterological Association Institute Technical Review. Gastroenterology, 154(4), 1103–1139.
• Whitcomb, D. C., Frulloni, L., Garg, P., et al. (2016). Chronic pancreatitis: An international draft consensus proposal for a new mechanistic definition. Pancreatology, 16(2), 218–224.
• American Association of Colleges of Nursing (AACN). (2021). The essentials: Core competencies for professional nursing education. AACN.
• QSEN Institute. (2020). QSEN competencies. Case Western Reserve University. https://qsen.org/competencies/pre-licensure-ksas/